Evidence map›Paper›PMID 24237985›Full record

ReviewPediatric clinics of North America2013

HUS and TTP in Children.

Howard Trachtman

Abstract readReview
In one paragraph

Review in Pediatric clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Diversity ofMicroorganisms · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Hemolytic uremic syndrome caused byKidney research and clinical practice · 2019
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Howard TrachtmanDivision of Nephrology, Department of Pediatrics, CTSI, NYU Langone Medical Center, 227 East 30th Street, Room #110, New York, NY 10016, USA. Electronic address: howard.trachtman@nyumc.org.

Funding

Novel Therapies for Resistant FSGSR33DK070341 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI TRACHTMAN, HOWARD · 2008 to 2011
$1.5M
Novel Therapies for Resistant FSGSR21DK070341 · NIDDK · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI TRACHTMAN, HOWARD · 2005 to 2006
$435k
International Network and Registry for TMAR21DK071221 · NIDDK · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI TRACHTMAN, HOWARD · 2006 to 2007
$405k
NIDDK NIH HHS R21 DK070341NIDDK NIH HHS R21 DK071221NIDDK NIH HHS R33 DK070341
6 · The paper itself

Abstract

This review describes the epidemiology, pathophysiology, presentation, clinical causes, treatment, and long-term prognosis of pediatric patients who present with thrombotic microangiopathy. The focus is on hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, the most common phenotypes of thrombotic microangiopathy.

Indexed as

ChildHemolytic-Uremic SyndromeHumansPurpura, Thrombotic ThrombocytopenicAlternative pathway of complement (APC)Hemolytic uremic syndrome (HUS)Shiga toxin (Stx)Thrombotic microangiopathy (TMA)Thrombotic thrombocytopenic purpura (TTP)

Identifiers

PMID24237985
PMCPMC3972058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.